AGC's Japanese and Danish factories to produce German biotech firm's drug candidate

German 4teen4 has chosen AGC Biologics as contract developer for the clinical testing of its drug candidate, procizumab.

In August, AGC broke ground on an expansion of its factory in Hillerød, Copenhagen | Photo: AGC Biologics / PR

Contract manufacturing organization AGC Biologics has entered into a partnership with biotech company 4teen4 Pharmaceuticals to produce the latter firm's drug candidate, procizumab, according to an AGC press release.

Procizumab is a monoclonal antibody designed as a potential treatment for circulatory diseases. Having gone through preclinical testing, the candidate is now ready for human trials – which is where AGC steps in to manufacture clinical trial materials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs